ArticleThe journal of prevention of Alzheimer's disease2025
Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].
Erika N Cline et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.